HC Wainwright Downgrades Vigil Neuroscience (NASDAQ:VIGL) to Hold

Vigil Neuroscience (NASDAQ:VIGL) was downgraded by equities research analysts at HC Wainwright from a “strong-buy” rating to a “hold” rating in a research note issued on Tuesday, Marketbeat Ratings reports. They presently have a $8.00 target price on the stock, down from their prior target price of $14.00. HC Wainwright’s price target would suggest a potential upside of 1.52% from the stock’s current price.

Other equities analysts have also recently issued research reports about the company. Citizens Jmp cut Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 22nd. Guggenheim set a $8.00 price target on Vigil Neuroscience and gave the stock a “neutral” rating in a research report on Thursday, May 22nd. Citigroup lowered Vigil Neuroscience to a “market perform” rating in a report on Thursday, May 22nd. William Blair cut shares of Vigil Neuroscience from a “strong-buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Finally, Jefferies Financial Group cut shares of Vigil Neuroscience to a “hold” rating in a research report on Thursday, May 22nd. Nine analysts have rated the stock with a hold rating, According to MarketBeat.com, Vigil Neuroscience currently has a consensus rating of “Hold” and a consensus price target of $11.50.

Vigil Neuroscience Stock Down 0.1%

Shares of NASDAQ VIGL opened at $7.88 on Tuesday. The firm has a market cap of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. The company’s 50-day simple moving average is $2.43 and its 200-day simple moving average is $2.35. Vigil Neuroscience has a 52-week low of $1.31 and a 52-week high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL) last issued its quarterly earnings results on Wednesday, May 7th. The company reported ($0.49) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.04. Equities research analysts anticipate that Vigil Neuroscience will post -2.07 EPS for the current fiscal year.

Hedge Funds Weigh In On Vigil Neuroscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BVF Inc. IL grew its holdings in Vigil Neuroscience by 121.3% in the 1st quarter. BVF Inc. IL now owns 4,013,633 shares of the company’s stock valued at $7,144,000 after buying an additional 2,200,000 shares in the last quarter. 683 Capital Management LLC boosted its position in shares of Vigil Neuroscience by 24.3% during the 1st quarter. 683 Capital Management LLC now owns 1,740,000 shares of the company’s stock valued at $3,097,000 after acquiring an additional 340,000 shares during the last quarter. Aberdeen Group plc grew its holdings in shares of Vigil Neuroscience by 226.3% in the first quarter. Aberdeen Group plc now owns 1,724,520 shares of the company’s stock valued at $3,070,000 after purchasing an additional 1,196,048 shares during the period. Blair William & Co. IL grew its holdings in shares of Vigil Neuroscience by 219.1% in the first quarter. Blair William & Co. IL now owns 1,033,577 shares of the company’s stock valued at $1,840,000 after purchasing an additional 709,677 shares during the period. Finally, Ensign Peak Advisors Inc increased its position in Vigil Neuroscience by 16.1% during the fourth quarter. Ensign Peak Advisors Inc now owns 703,116 shares of the company’s stock worth $1,195,000 after purchasing an additional 97,580 shares during the last quarter. Institutional investors and hedge funds own 83.64% of the company’s stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.